Washington, DC - October 19-23, 2022; Glasgow, Scotland and virtual - October 23-26, 2022
Investigators state that data support effectiveness, safety, and persistence of BIC/FTC/TAF in treatment-naive and treatment-experienced PWH with a high prevalence of comorbidities at baseline.